Codiak Reports Positive Initial Data for exoSTING™ Phase 1/2 Trial Indicating Tolerability, Immune Activation, and Evidence of Tumor Shrinkage in Injected and Non-Injected Tumors in the First Three Dose Escalation Cohorts
– exoSTING resulted in localized STING pathway activation and dose-dependent immune activation – – Intratumoral…
TransNusa Expands Regional Network With Launch of Jakarta-Penang Route
PLN Strengthens Its Pathway to the Global Carbon Market Through Energy Transition Investments
IMPC Commits Rp250 billion (USD 15 million) to Build ASEAN’s Leading Polymer Training Center, Partnering with SKZ-German Plastics Center
Bitzero Holdings Inc. Announces Commencement of Trading on Canadian Securities Exchange
OTTICA By Optimax Eyewear Launches New Online Platform for Luxury Eyewear Shopping